Evaluating KL-6 levels in lung disease related to rheumatoid arthritis
Official title: Value of Krebs Von Den Lungen-6 Assay in Rheumatoid Artheritis-associated Interstitial Lung Disease
Run by Assiut University · NCT05979454 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is testing if measuring KL-6 levels in the blood can help doctors better understand and treat lung problems in people with rheumatoid arthritis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT05979454 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with rheumatoid arthritis who also have interstitial lung disease.
✕Probably not a fit
Patients with rheumatoid arthritis who do not have interstitial lung disease or those with evidence of infection will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the serum levels of Krebs von den Lungen-6 (KL-6) in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). KL-6 is a glycoprotein that serves as a marker for pulmonary epithelial cell injury and has been associated with disease severity in various interstitial lung diseases. The study will assess the potential of KL-6 as a diagnostic and prognostic tool specifically for RA-ILD, which is a significant cause of morbidity and mortality in patients with rheumatoid arthritis. By understanding KL-6 levels, the study seeks to improve monitoring and treatment responses for affected patients.
Why it matters
Potential benefit: If successful, this study could provide a valuable diagnostic and prognostic tool for managing lung disease in rheumatoid arthritis patients.
How similar studies have gone: Previous studies have shown KL-6 to be a valuable marker in other interstitial lung diseases, suggesting potential success in this novel application for RA-ILD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010. Inclusion Criteria: * all patients have rheumatoid arthritis-associated interstitial lung disease Exclusion Criteria: * Patients with any evidence of infection will be excluded.
Where it's running
-
Safaa A Eid
Assiut, Egypt Recruiting
Study contacts
- Principal investigator: Safaa A Eid, Fellow — Assiut University
- Study coordinator: Safaa A Eid, Fellow
- Email: safaa_gayed@aun.edu.eg
- Phone: +20 01002569966
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated Traditional Chinese and Western treatment for rheumatoid arthritis
This project will try combining Traditional Chinese Medicine with Western treatments in people with rheumatoid arthritis, including those with difficult-to-treat disease and lung involvement.
-
Collecting biological samples from individuals with and without lung disease
This study is collecting blood, urine, and airway samples from both healthy people and those with lung diseases to see how their biology differs and learn more about these conditions.
-
Evaluating Genakumab for Lung Disease Related to Connective Tissue Disorders
This study is testing whether an injection called Genakumab can help people with lung disease caused by connective tissue disorders like rheumatoid arthritis and systemic sclerosis feel better.
-
Detecting lung issues in rheumatoid arthritis patients
This study is trying to create an easy-to-use online tool and app to help find lung problems in people with rheumatoid arthritis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.